{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=11", "query": { "intervention": "atezolizumab", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 512, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atezolizumab&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-13T22:37:12.983Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03386721", "title": "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers" ], "interventions": [ { "name": "simlukafusp alfa", "type": "DRUG" }, { "name": "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2018-02-19", "completion_date": "2021-12-30", "has_results": true, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 2, "location_summary": "San Francisco, California • Newnan, Georgia", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386721" }, { "nct_id": "NCT02302807", "title": "A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Vinflunine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 931, "start_date": "2015-01-13", "completion_date": "2018-11-08", "has_results": true, "last_update_posted_date": "2019-08-01", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 6, "location_summary": "Washington D.C., District of Columbia • Atlanta, Georgia • Las Vegas, Nevada + 3 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Greenville", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02302807" }, { "nct_id": "NCT03050814", "title": "Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Tumors", "Colorectal Neoplasms", "Colorectal Carcinoma", "Colorectal Adenocarcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Avelumab", "type": "DRUG" }, { "name": "Ad-CEA vaccine", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "5-Fluorouracil (FU)", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2017-04-05", "completion_date": "2021-08-25", "has_results": true, "last_update_posted_date": "2021-12-20", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03050814" }, { "nct_id": "NCT06712355", "title": "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Extensive-stage Small-cell Lung Cancer" ], "interventions": [ { "name": "Pumitamig", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin (or cisplatin if carboplatin is not tolerated)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 621, "start_date": "2025-02-03", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 36, "location_summary": "Tucson, Arizona • Clermont, Florida • Palm Bay, Florida + 29 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Clermont", "state": "Florida" }, { "city": "Palm Bay", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Niles", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06712355" }, { "nct_id": "NCT02495636", "title": "Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "CDX-1401", "type": "DRUG" }, { "name": "MPDL3280A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2015-07", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2017-06-22", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02495636" }, { "nct_id": "NCT06416436", "title": "Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Stereotactic Ablative Radiotherapy (SBRT)", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Kansas Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-07-15", "completion_date": "2024-07-15", "has_results": false, "last_update_posted_date": "2025-06-29", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 1, "location_summary": "Kansas City, Kansas", "locations": [ { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06416436" }, { "nct_id": "NCT05798663", "title": "Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Tiragolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2023-12-07", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 15, "location_summary": "La Jolla, California • Oakland, California • Roseville, California + 11 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Clara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05798663" }, { "nct_id": "NCT03618953", "title": "This is a Trial of MG1-E6E7 With Ad-E6E7 and Atezolizumab in Patients With HPV Associated Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HPV-Associated Cancers" ], "interventions": [ { "name": "Ad-E6E7", "type": "BIOLOGICAL" }, { "name": "MG1-E6E7", "type": "BIOLOGICAL" }, { "name": "Atezolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Turnstone Biologics, Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-06-21", "completion_date": "2021-03-05", "has_results": false, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 5, "location_summary": "Miami, Florida • Billings, Montana • New York, New York + 2 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Billings", "state": "Montana" }, { "city": "New York", "state": "New York" }, { "city": "Toledo", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03618953" }, { "nct_id": "NCT03196401", "title": "A Study of Durvalumab (Anti-PDL1) Plus Radiation Therapy for the Treatment of Solitary Bone Plasmacytoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solitary Bone Plasmacytoma" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2017-07-27", "completion_date": "2020-06", "has_results": false, "last_update_posted_date": "2018-08-03", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 6, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03196401" }, { "nct_id": "NCT07195695", "title": "Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Zongertinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 400, "start_date": "2026-01-16", "completion_date": "2036-09-02", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-13T22:37:12.983Z", "location_count": 27, "location_summary": "Fresno, California • Glendale, California • Orange, California + 21 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07195695" } ] }